"Anemia is found in about one-third of all cases of congestive heart failure (CHF). The most likely common cause is chronic kidney insufficiency (CKI), which is present in about half of all CHF cases. The CKI is likely to be due to the renal vasoconstriction that often accompanies CHF and can cause long-standing renal ischemia. This reduces the amount of erythropoietin (EPO) produced in the kidney and leads to anemia. However, anemia can occur in CHF without CKI and is likely to be due to excessive cytokine production (for example, tumor necrosis factor-alfa (TNF-alfa) and interleukin-6 (IL-6)), which is common in CHF and can cause reduced EPO secretion, interference with EPO activity in the bone marrow and reduced iron supply to the bone marrow. The anemia itself can worsen cardiac function, both because it causes cardiac stress through tachycardia and increased stroke volume, and because it can cause a reduced renal blood flow and fluid retention, adding further stress to the heart. Long-standing anemia of any cause can cause left ventricular hypertrophy (LVH), which can lead to cardiac cell death through apoptosis and worsen the CHF. Therefore, a vicious circle is set up wherein CHF causes anemia, and the anemia causes more CHF and both damage the kidneys worsening the anemia and the CHF further. We have termed this vicious circle the cardio renal anemia (CRA) syndrome. Patients with CHF who are anemic are often resistant to all CHF medications resulting in being hospitalized repeatedly. Many studies also demonstrate that these patients die more rapidly than their non-anemic counterparts do. In addition, they have a more rapid deterioration in their renal function and can end up on dialysis. There is now evidence from both uncontrolled and controlled studies that early correction of the CHF anemia with subcutaneous EPO and intravenous (i.v.) iron improves shortness of breath and fatigue, cardiac function, renal function and exercise capability, dramatically reducing the need for hospitalization. For these reasons, it is not surprising that quality of life has also been shown to improve. As both CHF and end-stage renal disease (ESRD) are rapidly increasing, the possibility that these twin conditions can be improved by the adequate treatment of anemia offers new hope for slowing the progression of both conditions."
Updates on the Association Between Anemia and Heart Failure: A Systematic Review (2024)
Mirghani H, Alshareif A A, Al-Temani H A, et al. (September 10, 2024) Updates on the Association Between Anemia and Heart Failure: A Systematic Review. Cureus 16(9): e69101. doi:10.7759/cureus.69101
Updates on the Association Between Anemia and Heart Failure: A Systematic Review (2024)
Mirghani H, Alshareif A A, Al-Temani H A, et al. (September 10, 2024) Updates on the Association Between Anemia and Heart Failure: A Systematic Review. Cureus 16(9): e69101. doi:10.7759/cureus.69101
This is an open access cite--I'm not familiar with it.
Abstract of update: This systematic review aims to investigate the potential relationship between anemia and heart failure (HF) by summarizing existing literature on the topic. A comprehensive search was performed using four major databases, PubMed, Scopus, Web of Science, and ScienceDirect, to find the relevant literature. Ten studies, including a total of 2,828 participants, with 1,451 (51.3%) males, were included in this review. Iron deficiency anemia was the most prevalent type in the included studies; however, two studies included megaloblastic anemia. The prevalence of anemia in patients diagnosed with HF ranged from 33.3% to 69.8%, with a total prevalence of 1,643 (58.1%). Hypertension, diabetes mellitus, chronic kidney disease, and atrial fibrillation were the most commonly associated comorbidities in patients with HF. Anemia patients had a considerably higher risk of mortality than those without anemia. Anemia served as a marker of disease severity rather than an independent predictor of death in congestive individuals. Anemia was substantially correlated with elevated serum creatinine, left ventricular hypertrophy, and left atrial enlargement. According to the findings of this review, anemia has a significant impact on the prognosis of HF. In patients with HF, anemia may be a reliable indicator of both short- and long-term all-cause mortality as well as the rates of all-cause HF events. Future and ongoing research may provide vital information that may help guide clinical judgments in the future.
intravenous ferric carboxymaltose treatment
Intravenous ferric carboxymaltose for iron deficiency in heart failure patients: A meta-analysis with trial sequential analysis European Journal of Pharmacology, 5 December 2025 Laila Shalabi,Ahmed Ibrahim,Shrouk Ramadan,Sofian Zreigh,Shahed Shalabi,Mohamed Rifai,Abdelaziz A. Awad,Abdelrahman Mamdouh Ahmed,Matthieu Legrand,Dan Meyer,
Abstract
Background
Iron deficiency is present in roughly one-third to one-half of patients with chronic heart failure and is associated with worse outcomes. In this study, we aim to assess the impact of intravenous (IV) ferric carboxymaltose (FCM) administration on heart failure outcomes.
Methods
We performed a comprehensive literature search of PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) up to May 2025. The outcomes of interest, including first heart failure hospitalization or cardiovascular death (primary outcome), total heart failure hospitalizations, and total all-cause hospitalization, were estimated using a fixed-effect model and reported as pooled risk ratios (RRs). Trial sequential analysis (TSA) was conducted to assess the robustness of the findings and estimate the required information size.
Results
Nine RCTs were included, comprising 7491 patients. Compared to placebo, FCM significantly reduced the risk of hospitalization due to heart failure or cardiovascular death (RR 0.89, 95 % CI 0.83–0.96; P = 0.0016). Additionally, FCM lowered the risk of heart failure hospitalizations (RR 0.82, 95 % CI 0.77–0.87; P < 0.0001) and decreased the risk of cardiovascular death (RR 0.89, 95 % CI 0.80–0.99; P = 0.0384). However, there was no significant difference in total all-cause hospitalization between the groups (RR 0.93, 95 % CI 0.85–1.01; P = 0.0830). TSA demonstrated conclusive evidence for the primary outcome.
Conclusion
FCM reduces the risk of heart failure hospitalizations, cardiovascular hospitalizations, and cardiovascular death in iron-deficient heart failure patients, although it does not impact all-cause hospitalization, thereby supporting its utility as a targeted therapeutic strategy.
PROSPERO ID
CRD420251062092.